Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805990 | 1.00 | ADRB3 (0.39) | ADRB3ADRB2CYP1A2ALDH1A1CYP2C9 | |
| SCHEMBL17660490 | 0.87 | KMT2A (0.39) | ADRB3ADRB2CYP1A2ALDH1A1CYP2C9 | |
| SCHEMBL5391885 | 0.85 | ADRB3 (0.45) | ADRB3ADRB2ADRB1ADRA2AADRA2B | |
| SCHEMBL5401549 | 0.83 | ADRB2 (0.39) | ADRB3ADRB2CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL25708294 | 0.81 | ADRB3 (0.47) | ADRB3ADRB2ADRA1DMEN1KMT2A | |
| SCHEMBL4801268 | 0.81 | ADRB3 (0.47) | ADRB3ADRB2ADRA1DMEN1KMT2A | |
| SCHEMBL5384330 | 0.80 | ADRB2 (0.37) | ADRB3ADRB2CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL5385110 | 0.79 | ROCK2 (0.38) | ALDH1A1 | |
| SCHEMBL5381523 | 0.79 | ROCK2 (0.38) | ALDH1A1 | |
| SCHEMBL2831936 | 0.79 | ADRB2 (0.41) | ADRB3ADRB2CYP1A2ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294725-B1 | Process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294725-B1 | Process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294725-B1 | Process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-6911560-B2 | Process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030162840-A1 | Novel process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION | 2003-08-28 | — | — | US | disclosed |
| EP-1289926-A2 | A NOVEL PROCESS FOR PREPARING SALMETEROL | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096278-A2 | A NOVEL PROCESS FOR PREPARING SALMETEROL | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162840-A1 | Novel process for preparing salmeterol | HSD11B1, HSD3B1, HSD11B2 | ADRB3 59/4885ADRB2 37/4885CYP1A2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.